TY - JOUR
T1 - Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients
AU - Lindegaard, B
AU - Keller, P
AU - Bruunsgaard, H
AU - Gerstoft, J
AU - Pedersen, B K
PY - 2004/2
Y1 - 2004/2
N2 - This study tested the hypothesis that in patients with HIV-associated lipodystrophy, adiponectin levels were related to insulin resistance, TNF-alpha and IL-6 and treatment with nucleoside analogues. HIV seropositive men undergoing highly active antiretroviral treatment were enrolled into three predetermined clinical groups: lipodystrophy with central fat accumulation (n = 12); lipodystrophy without central fat accumulation (n = 15); no lipodystrophy (n = 15). HIV-negative healthy men served as controls (n = 12). Both lipodystrophic groups had a low percentage of limb fat compared to the two control groups. Patients with lipodystrophy with fat accumulation had increased truncal fat compared with controls. Levels of adiponectin did not correlate with either TNF-alpha or IL-6. Low levels of adiponectin were found in both lipodystrophic groups and were associated with current or previous treatment with stavudine. Furthermore, the adiponectin level correlated with the percentage of limb fat. Patients with lipodystrophy with fat accumulation were more insulin resistant, measured by HOMA-IR, compared with controls. However, HOMA-IR did no correlate to adiponectin or other cytokines. In conclusion, the finding of no difference between the two lipodystrophic groups with regard to adiponectin, indicates that low levels of adiponectin reflects fat atrophy, whereas the insulin resistance was best explained by increased truncal fat mass.
AB - This study tested the hypothesis that in patients with HIV-associated lipodystrophy, adiponectin levels were related to insulin resistance, TNF-alpha and IL-6 and treatment with nucleoside analogues. HIV seropositive men undergoing highly active antiretroviral treatment were enrolled into three predetermined clinical groups: lipodystrophy with central fat accumulation (n = 12); lipodystrophy without central fat accumulation (n = 15); no lipodystrophy (n = 15). HIV-negative healthy men served as controls (n = 12). Both lipodystrophic groups had a low percentage of limb fat compared to the two control groups. Patients with lipodystrophy with fat accumulation had increased truncal fat compared with controls. Levels of adiponectin did not correlate with either TNF-alpha or IL-6. Low levels of adiponectin were found in both lipodystrophic groups and were associated with current or previous treatment with stavudine. Furthermore, the adiponectin level correlated with the percentage of limb fat. Patients with lipodystrophy with fat accumulation were more insulin resistant, measured by HOMA-IR, compared with controls. However, HOMA-IR did no correlate to adiponectin or other cytokines. In conclusion, the finding of no difference between the two lipodystrophic groups with regard to adiponectin, indicates that low levels of adiponectin reflects fat atrophy, whereas the insulin resistance was best explained by increased truncal fat mass.
KW - Adiponectin
KW - Adipose Tissue/immunology
KW - Adult
KW - Aged
KW - Anti-HIV Agents/therapeutic use
KW - Antiretroviral Therapy, Highly Active/methods
KW - Body Composition
KW - HIV-Associated Lipodystrophy Syndrome/blood
KW - Humans
KW - Insulin/blood
KW - Insulin Resistance/immunology
KW - Intercellular Signaling Peptides and Proteins
KW - Interleukin-6/blood
KW - Male
KW - Middle Aged
KW - Protease Inhibitors/therapeutic use
KW - Proteins/analysis
KW - Reverse Transcriptase Inhibitors/therapeutic use
KW - Stavudine/therapeutic use
KW - Time Factors
KW - Tumor Necrosis Factor-alpha/analysis
U2 - 10.1111/j.1365-2249.2004.02367.x
DO - 10.1111/j.1365-2249.2004.02367.x
M3 - Journal article
C2 - 14738456
SN - 0009-9104
VL - 135
SP - 273
EP - 279
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 2
ER -